Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and VYNDAMAX™ (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are two oral formulations of the first-in-class transthyretin stabilizer tafamidis, and the first and only medicines approved by the FDA to treat ATTR-CM.
myBinderRelated Content
-
Treatment for ATTR Cardiomyopathy – ASG Webinar 2/7https://www.youtube.com/watch?v=IzC_yaqs...
-
Eidos Clinical Trial Update – ASG Webinar 5/11https://www.youtube.com/watch?v=K2TmwAfu...
-
ISA 2020 | 99mTc-DPD Scintigraphy Predicts Amyloid Fibril Type in ATTR Amyloidosishttps://www.youtube.com/watch?v=losWZBVV...
-
Safety and Efficacy of Long-Term Diflunisal Administration in Hereditary Transthyretin (ATTR) AmyloidosisBackground: A recent 2-year randomized ...
-
Q&A Session One with Drs. Lyle, Cheng, Karam – ASG Webinar 7.15.23 – 6/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic ReviewImportance: Many patients with systemic ...
-
Hereditary ATTR Val122Ile Cardiac AmyloidosisHereditary ATTR amyloidosis is an inheri...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
